Research on WTP per QALY in Asia (collaborated with members in NECA (Korea) and HITAP (Thailand)

Generally, an intervention is considered cost-effective if the ICER (e.g.,cost per QALY) is below a predetermined threshold.
For example, £20,000-£30,000 per QALY has been accepted as the threshold by NICE. In the US, the threshold of US$ 50,000-$100,000 per QALY often is mentioned. In Japan, there is no consensus on the threshold of cost-effectiveness. We will survey on the monetary value of one QALY using such as contingent valuation method (CVM).
This survey is collaborated with members in NECA (Korea) and HITAP (Thailand).
We are now discussing the common methodology which will be applied in the three countries. We expect this study, based on the common approach, improves comparability of the results and leads to more reliable decision making by economic evaluation.

Research group on HTA funded by MHLW (PI: T. Fukuda):

Although Japanese authorities hardly use economic evaluation or health technology assessment (HTA) for their decision-making, the Ministry of Health, Labor and Welfare (MHLW) begins to have interest in them.
They visited HTA agency and interviewed in some foreign countries (UK, Sweden,Netherlands, Australia, Korea, Thailand, Canada) in 2011. Based on these interviews they considered applicable system to Japanese setting (such as reimbursement and pricing).

Research group on vaccination funded by MHLW (PI: S. Ikeda):

In Japan there are some vaccinations which were not funded by local government. Some of them are widely used in the world, such as the Haemophilus influenzae type b (Hib) vaccine, 7-valent pneumococcal conjugate vaccine (PCV7), and human papillomavirus (HPV) vaccine.
To support MHLW's decision making (which vaccination should be funded ?), they performed cost-effective analysis on 7 unfunded vaccination program (Hib, PCV7(children), Varicella, Mumps, HBV, HPV, PCV23(adults)) based on the same analytical methods for comparability.

Back to Pagetop